1. Home
  2. IMNN vs TLPH Comparison

IMNN vs TLPH Comparison

Compare IMNN & TLPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMNN
  • TLPH
  • Stock Information
  • Founded
  • IMNN 1982
  • TLPH 2005
  • Country
  • IMNN United States
  • TLPH United States
  • Employees
  • IMNN N/A
  • TLPH N/A
  • Industry
  • IMNN Biotechnology: Pharmaceutical Preparations
  • TLPH Biotechnology: Pharmaceutical Preparations
  • Sector
  • IMNN Health Care
  • TLPH Health Care
  • Exchange
  • IMNN Nasdaq
  • TLPH Nasdaq
  • Market Cap
  • IMNN 12.1M
  • TLPH 11.1M
  • IPO Year
  • IMNN 1985
  • TLPH 2011
  • Fundamental
  • Price
  • IMNN $5.75
  • TLPH $0.93
  • Analyst Decision
  • IMNN Buy
  • TLPH Strong Buy
  • Analyst Count
  • IMNN 2
  • TLPH 1
  • Target Price
  • IMNN $182.61
  • TLPH $6.00
  • AVG Volume (30 Days)
  • IMNN 55.7K
  • TLPH 7.3M
  • Earning Date
  • IMNN 11-06-2025
  • TLPH 11-12-2025
  • Dividend Yield
  • IMNN N/A
  • TLPH N/A
  • EPS Growth
  • IMNN N/A
  • TLPH N/A
  • EPS
  • IMNN N/A
  • TLPH N/A
  • Revenue
  • IMNN N/A
  • TLPH $27,000.00
  • Revenue This Year
  • IMNN N/A
  • TLPH N/A
  • Revenue Next Year
  • IMNN N/A
  • TLPH $14,533.26
  • P/E Ratio
  • IMNN N/A
  • TLPH N/A
  • Revenue Growth
  • IMNN N/A
  • TLPH N/A
  • 52 Week Low
  • IMNN $4.83
  • TLPH $0.38
  • 52 Week High
  • IMNN $41.22
  • TLPH $1.20
  • Technical
  • Relative Strength Index (RSI)
  • IMNN 36.86
  • TLPH 79.40
  • Support Level
  • IMNN $5.53
  • TLPH $0.40
  • Resistance Level
  • IMNN $5.89
  • TLPH $1.07
  • Average True Range (ATR)
  • IMNN 0.32
  • TLPH 0.13
  • MACD
  • IMNN 0.07
  • TLPH 0.05
  • Stochastic Oscillator
  • IMNN 23.81
  • TLPH 61.44

About IMNN Imunon Inc.

Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).

About TLPH Talphera Inc.

Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.

Share on Social Networks: